Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
8.35
+0.21 (2.58%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.
The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Daxor Corporation
| Country | United States |
| Founded | 1970 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Michael Feldschuh |
Contact Details
Address: 109 Meco Lane Oak Ridge, Tennessee 37830 United States | |
| Website | daxor.com |
Stock Details
| Ticker Symbol | DXR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000027367 |
| CUSIP Number | 239467103 |
| ISIN Number | US2394671034 |
| Employer ID | 13-2682108 |
Key Executives
| Name | Position |
|---|---|
| Michael Richard Feldschuh | Chairman, President and Chief Executive Officer |
| Jonathan Adam Feldschuh | Chief Scientific Officer and Director |
| Robert J. Michel CPA, CPA, M.B.A. | Chief Financial Officer, Chief Compliance Officer and Corporate Secretary |
| Linda Cooper | Vice President of Development and Operations |
| Kathryn A. Kornafel | Senior Vice President of Marketing and Commercial Development |
| Guido Manzo | Vice President of Sales |
| Jean Oertel | Senior Vice President Commercialization and Customer Experience |
| Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Sep 10, 2024 | N-PX | Annual Report of proxy voting record of management investment companies |
| Aug 29, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Aug 29, 2024 | N-CSRS | Filing |
| Aug 23, 2024 | 40-17G | Filing |
| Aug 16, 2024 | N-2 | Filing |
| Jul 18, 2024 | 8-K | Current Report |
| Jun 21, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 5, 2024 | 8-K | Current Report |
| May 30, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |